Clinical trials
SGLT2 Inhibitors clinical trials
Below are recruiting sglt2 inhibitors clinical trials, each written for real people, not researchers. We’re tracking 41 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07214818RecruitingPhase 2/Phase 3
SGLT2 Inhibitors for Adult Primary Nephrotic Syndrome
This trial tests whether SGLT2 inhibitors (a type of diabetes medicine) can help adults with primary nephrotic syndrome, a kidney disease that causes protein leakage and swelling. It aims to see if the drug can protect kidney function and reduce protein loss.
Al Mansurah, Dakahlia GovernorateAges 18 years+ - NCT06929169RecruitingPhase 2
SGLT2 inhibitor heart health study in dialysis patients
This study tests whether a medicine called an SGLT2 inhibitor (a type of diabetes drug also used for heart failure) affects the heart and blood vessels in people with kidney failure who are on dialysis. It will help doctors understand if this medicine is safe and helpful for dialysis patients.
Buenos Aires, Buenos AiresAges 18–70 - NCT07174687RecruitingPhase 2
SGLT2 inhibitor for geographic atrophy
This study tests an SGLT2 inhibitor (dapagliflozin) as a possible treatment for geographic atrophy, a progressive form of dry age-related macular degeneration that causes vision loss. It is for people who meet specific eye and health criteria.
St Louis, MissouriAges 50 years+ - NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT07038356RecruitingPhase 3
Continuing empagliflozin during heart failure hospitalizations
This study tests whether continuing empagliflozin (a heart failure medicine) during a hospital stay for heart failure is beneficial compared to stopping it. Participation may help improve recovery and reduce complications.
Jena, ThuringiaAges 18 years+ - NCT06932081Recruiting
Study of SGLT2i in adults with congenital heart disease
This trial is a registry that follows adults with congenital heart disease who have started taking an SGLT2 inhibitor medication. The goal is to learn how well this treatment works for this group of patients.
Baltimore, MarylandAges 18 years+ - NCT06609356RecruitingEarly Phase 1
Reducing high insulin levels in type 1 diabetes
This study tests if adding a non-insulin medication can lower the amount of insulin needed while improving heart and metabolic health in people with type 1 diabetes. It may also help understand how this approach works in people with a genetic form of diabetes (GCK-MODY).
Nashville, TennesseeAges 18–60 - NCT06600178RecruitingPhase 1
Heart medication for women with chest pain and small vessel disease
This trial tests a diabetes medication called SGLT2 inhibitors to see if it can improve blood flow to the heart and reduce chest pain in women who have small vessel heart disease (microvascular dysfunction) but not blocked large arteries. Participants will take the medication and be monitored for symptom relief and heart function improvements.
Charlottesville, VirginiaAges 18 years+ - NCT06055452RecruitingPhase 4
SGLT2 Inhibitors for Pre-Heart Failure with Hypertension
This trial tests if a medicine (SGLT2 inhibitor) given to people with high blood pressure and early signs of heart stress can help prevent heart failure. You may join if your blood pressure is controlled but tests show your heart is beginning to struggle.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05669742RecruitingPhase 3
Empagliflozin plus olanzapine to reduce metabolic side effects
This trial tests whether adding empagliflozin to standard olanzapine treatment can improve metabolic problems (like blood sugar and cholesterol changes) that can happen with olanzapine in people with schizophrenia. If you qualify, you would be closely monitored for benefits and side effects.
TantaAges 18–65 - NCT05390892RecruitingPhase 4
Preventing kidney and heart damage in type 2 diabetes
This study tests whether diabetes medicines can help prevent worsening heart and kidney problems in people with type 2 diabetes. You’ll be assigned by chance to one of these medicine types, and your other care will be adjusted for safety.
Huntsville, AlabamaAges 40–80 - NCT05057806RecruitingEarly Phase 1
Testing how ketones may affect heart benefits in type 2 diabetes
This early study looks at people with type 2 diabetes and certain types of heart failure to see whether changes in “ketones” relate to heart benefits. It may help researchers understand who could benefit most from treatment-related metabolism changes.
San Antonio, TexasAges 18–80 - NCT03878706Recruiting
Testing diabetes medicines on heart risk and heart failure
This trial studies how diabetes medicines (GLP-1 and SGLT2, alone or together) affect the heart in people with type 2 diabetes who are at higher cardiovascular risk and have heart failure with preserved pumping function. It may help find safer or more effective ways to reduce heart problems.
Athens, AtticaAges 45–80 - NCT06972732RecruitingPhase 4
Comparing three diabetes drugs for type 2 diabetes
This trial tests a combination of three common diabetes medications (metformin, an SGLT2 inhibitor, and a TZD) to see how well they work together and if they are safe. It may help people with type 2 diabetes who need better blood sugar control.
Seoul, Seocho DistrictAges 19 years+ - NCT06443645Recruiting
Protecting the heart during breast cancer treatment
This trial tests whether a diabetes medicine (SGLT2 inhibitor) can prevent heart damage caused by a common chemotherapy drug (anthracycline) in people with early-stage breast cancer. If you are newly diagnosed and about to start chemotherapy or have surgery, this study may be for you.
StrasbourgAges 18 years+ - NCT05305911RecruitingPhase 2
SGLT2 drug after first heart attack to reduce heart damage
This Phase 2 trial tests whether an SGLT2 medicine started after a first STEMI heart attack can reduce ongoing heart muscle injury and scarring. It may help people who, based on heart imaging, have larger infarcts and ongoing microvascular damage.
Minneapolis, MinnesotaAges 18–75 - NCT05715814RecruitingPhase 3
Test diabetes-pill type medicine on kidney dialysis safety
This Phase 3 trial studies the safety of an SGLT2 inhibitor (a diabetes medication that can affect kidney fluid handling) in people on peritoneal dialysis. The goal is to see how the treatment works in your type of dialysis and whether it causes any problems.
Toronto, OntarioAges 18 years+
Hear when a new SGLT2 Inhibitors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sglt2 inhibitors?
- Yes. Clin2 currently lists 41 recruiting sglt2 inhibitors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sglt2 inhibitors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sglt2 inhibitors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.